The US Is Cracking Down On Rogue Genetic Engineers
By Kristen V. Brown,
Gizmodo
| 01. 31. 2017
David Ishee’s plan was simple, if not exactly free of complication. From the shed that functions as his laboratory in rural Mississippi, he hoped to use genetic engineering to rid dogs of the types of terrible disorders caused by decades of high-end breeding.
Now, on top of the obvious scientific hurdles, Ishee has a new challenge to contend with: the US Food and Drug Administration (FDA).
Ishee is a biohacker, one among a growing number of do-it-yourself scientists that the US government is having an increasingly difficult time figuring out what to do with.
Since the DIY bio community first developed in the early naughts, it has largely avoided government regulation. But in 2017, cheaper equipment and simpler genetic engineering technologies mean that garage scientists can dream much bigger than simply turning yellow yeast red. We now live in a world where anyone can order custom DNA sequences on the internet to tinker with in their home. And the rules that govern genetic engineering today were not written with the foresight that it would one day be possible for...
Related Articles
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...